INDP

Indaptus Therapeutics Inc. (INDP) | Rumor.io

Indaptus Therapeutics

INDP

Attention (50-day avg)0%

Attention rank (50-day avg)#1,505

Bullish sentiment (50-day avg)91%

Price to earnings ratio-0.15

Market capitalization438.4M

Earnings per share-3.04

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-20.8M

Social

What share of all stock conversation is about INDP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 15

The stock of Indaptus Therapeutics, Inc. ($INDP) has seen significant price gains, with a 138.8% increase over five days, accompanied by a substantial rise in volume.
Analysts and traders have noted the unusual price action of $INDP, with some attributing it to a "no news pump" and others to a potential "mispricing of assets" that could lead to a 40% correction.
There are concerns about the valuation of $INDP, with some traders questioning whether the stock is worth its current price, given its lack of clinical trials and revenue, and others speculating that the stock could be a "reverse merger shell BS" with insiders being "con artists."

Generated by AI

Sentiment

Of the messages about INDP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +7.14	92.22% +8.89	72.98% -4.33
Bearish	—	0% -7.14	7.78% -8.89	27.02% +4.33

Bullish· Jun 11

$INDP is reclaiming short-term moving averages with RSI staying elevated, setting up a potential multi-day momentum play.
$INDP is pushing higher with strong momentum after a massive +36% move, with price holding above key intraday EMAs and volume staying elevated.
$INDP is showing classic momentum behavior, with heavy volume, strong trend structure, and higher lows forming intraday, with a clean break over $3.43 potentially triggering another squeeze leg.

Bearish· Jun 4

$INDP's recent price spike was short-lived and followed by a decline, suggesting a lack of sustained momentum.
The company's decision to pursue Decoy trials rather than a reverse merger may have contributed to the stock's decline, as some investors had been expecting a different direction.
The high volume of short selling and the large number of bags in the stock suggest a significant amount of bearish sentiment and potential downward pressure on the price.

Generated by AI

Topics

Of the messages about INDP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	75%	9.63%	28.66%
Technical Analysis	100%	25%	2.14%	17.8%
Analysts	0%	0%	44.12%	27.9%
Macro	0%	0%	44.12%	25.04%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0.6%

Announcements· Dec 29

Indaptus Therapeutics ($INDP) enters into a $6 million securities purchase agreement with investor David E. Lazar, strengthening its balance sheet.
David E. Lazar is appointed as Indaptus' Co-Chief Executive Officer and Chairman of the Board as part of the agreement.
The transaction aims to enhance liquidity and support Indaptus' future development and operational programs.

Technical Analysis· Dec 24

INDP is breaking a trend and may be due for a breakout.
The stock is showing signs of accumulation and potential for a bullish long opportunity, particularly after a dip and pre-market strength.
INDP has been forming a falling wedge pattern, with a breakout imminent and potential for rapid rallies.

Generated by AI

Community

Of the messages about INDP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	8.33%	16.17%	19.99%
Newcomers	100%	91.67%	83.83%	80.01%

Regulars· Sep 8

The regulars are waiting for quality setups and are monitoring $INDP, $GPRO, $NUR, and $BNC for entry confirmation.
$INDP is unusually active in the premarket and selling time is at 1.8, according to the regulars.
The regulars are highlighting $INDP's performance, with one member claiming to have caught the stock at $1.29 and selling at $1.82, and another member stating that the stock is "not bad for a stock nobody was talking about this morning."

Newcomers· Sep 9

The stock has seen a significant surge, with a 50.8% increase on September 8, 2026, but the SEC filings reveal a complicated story behind the move.
The stock's recent price action has been driven by heavy volume, with some speculating that it may be a liquidity event for trapped position holders.
The company has a significant overhang of outstanding warrants, which could impact its ability to raise capital through public offerings or private placements.

Generated by AI

News

Indaptus Therapeutics Announces Private Equity Financing Deal

Detailed price information for Indaptus Therapeutics Inc (INDP-Q) from The Globe and Mail including charting and trades.

19d agoThe Globe and Mail

Indaptus Therapeutics Shares Rise After Entering $24 Million Private Placement

Indaptus Therapeutics (INDP) shares rose nearly 22% in Thursday afternoon trading after the company

20d agoYahoo Finance

12 Health Care Stocks Moving In Tuesday's Intraday Session

21d agoBenzinga

12 Health Care Stocks Moving In Thursday's Intraday Session

1mo agoBenzinga

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a biotechnology company dedicated to immunotherapy research, today announced financial results for the second quarter and six months ended June 30, 2026, and provided a corporate update. Junyi Dai, Indaptus Therapeutics' Chief Executive Officer and Chairman of the Board, commented, "During the second quarter, we strengthened the Company's balance sheet through a $12.0 million pri

1mo agoYahoo Finance

Also Discussed

Investors talking about INDP also mention

#	Name	Attention
1	U-BX Technology Ltd.UBXG	0%0
2	Mingteng International Corporation Inc.MTEN	0%0
3	MBCN - Middlefield Banc Corp.	——
4	Treace Medical Concepts Inc.TMCI	0%0
5	Samfine Creation Holdings Group Ltd. Class A Ordinary SharesSFHG	0%new
6	SPTN - SpartanNash Company	——
7	ICZOOM Group Inc. Class A Ordinary SharesIZM	0%0
8	Presidio Property Trust, Inc. Class A Common StockSQFT	0%new
9	DPSI - Decisionpoint Systems, Inc.	——
10	NFT Ltd. Class A Ordinary ShareMI	0%+0

Indaptus Therapeutics Inc.

Healthcare
Biotechnology

Indaptus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing immunotherapy products for cancer and viral infections. The company’s current work centers on its Decoy platform, a proprietary system designed to activate multiple components of the innate and adaptive immune system while aiming to reduce systemic toxicity. Its lead candidate, Decoy20, is being developed for a range of oncology and infectious disease applications, including solid tumors and chronic viral infections. Indaptus Therapeutics Inc. operates in the biopharmaceutical sector, where it contributes to research-driven drug development with an emphasis on novel immune-activating approaches. Based in New York, the company is primarily engaged in preclinical and clinical-stage development activities rather than commercial product sales.

Website

Location

Three Columbus Circle

New York, NY, 10019

United States

Social

What share of all stock conversation is about INDP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 15

The stock of Indaptus Therapeutics, Inc. ($INDP) has seen significant price gains, with a 138.8% increase over five days, accompanied by a substantial rise in volume.
Analysts and traders have noted the unusual price action of $INDP, with some attributing it to a "no news pump" and others to a potential "mispricing of assets" that could lead to a 40% correction.
There are concerns about the valuation of $INDP, with some traders questioning whether the stock is worth its current price, given its lack of clinical trials and revenue, and others speculating that the stock could be a "reverse merger shell BS" with insiders being "con artists."

Generated by AI

Sentiment

Of the messages about INDP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +7.14	92.22% +8.89	72.98% -4.33
Bearish	—	0% -7.14	7.78% -8.89	27.02% +4.33

Bullish· Jun 11

$INDP is reclaiming short-term moving averages with RSI staying elevated, setting up a potential multi-day momentum play.
$INDP is pushing higher with strong momentum after a massive +36% move, with price holding above key intraday EMAs and volume staying elevated.
$INDP is showing classic momentum behavior, with heavy volume, strong trend structure, and higher lows forming intraday, with a clean break over $3.43 potentially triggering another squeeze leg.

Bearish· Jun 4

$INDP's recent price spike was short-lived and followed by a decline, suggesting a lack of sustained momentum.
The company's decision to pursue Decoy trials rather than a reverse merger may have contributed to the stock's decline, as some investors had been expecting a different direction.
The high volume of short selling and the large number of bags in the stock suggest a significant amount of bearish sentiment and potential downward pressure on the price.

Generated by AI

Topics

Of the messages about INDP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	75%	9.63%	28.66%
Technical Analysis	100%	25%	2.14%	17.8%
Analysts	0%	0%	44.12%	27.9%
Macro	0%	0%	44.12%	25.04%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0.6%

Announcements· Dec 29

Indaptus Therapeutics ($INDP) enters into a $6 million securities purchase agreement with investor David E. Lazar, strengthening its balance sheet.
David E. Lazar is appointed as Indaptus' Co-Chief Executive Officer and Chairman of the Board as part of the agreement.
The transaction aims to enhance liquidity and support Indaptus' future development and operational programs.

Technical Analysis· Dec 24

INDP is breaking a trend and may be due for a breakout.
The stock is showing signs of accumulation and potential for a bullish long opportunity, particularly after a dip and pre-market strength.
INDP has been forming a falling wedge pattern, with a breakout imminent and potential for rapid rallies.

Generated by AI

Community

Of the messages about INDP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	8.33%	16.17%	19.99%
Newcomers	100%	91.67%	83.83%	80.01%

Regulars· Sep 8

The regulars are waiting for quality setups and are monitoring $INDP, $GPRO, $NUR, and $BNC for entry confirmation.
$INDP is unusually active in the premarket and selling time is at 1.8, according to the regulars.
The regulars are highlighting $INDP's performance, with one member claiming to have caught the stock at $1.29 and selling at $1.82, and another member stating that the stock is "not bad for a stock nobody was talking about this morning."

Newcomers· Sep 9

The stock has seen a significant surge, with a 50.8% increase on September 8, 2026, but the SEC filings reveal a complicated story behind the move.
The stock's recent price action has been driven by heavy volume, with some speculating that it may be a liquidity event for trapped position holders.
The company has a significant overhang of outstanding warrants, which could impact its ability to raise capital through public offerings or private placements.

Generated by AI

Indaptus Therapeutics

Social

Sep 15

Bullish· Jun 11

Bearish· Jun 4

Announcements· Dec 29

Technical Analysis· Dec 24

Regulars· Sep 8

Newcomers· Sep 9

Indaptus Therapeutics Announces Private Equity Financing Deal

Indaptus Therapeutics Shares Rise After Entering $24 Million Private Placement

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Thursday's Intraday Session

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Also Discussed

Indaptus Therapeutics Inc.

Company Information

Location

Indaptus Therapeutics Announces Private Equity Financing Deal

Indaptus Therapeutics Shares Rise After Entering $24 Million Private Placement

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Thursday's Intraday Session

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Also Discussed

Social

Sep 15

Bullish· Jun 11

Bearish· Jun 4

Announcements· Dec 29

Technical Analysis· Dec 24

Regulars· Sep 8

Newcomers· Sep 9